Real‐world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer

Real‐world data are lacking in assessing the real world effectiveness of fulvestrant monotherapy for use in post-menopausal women with hormone receptor-positive, metastatic breast cancer (MBC) who progressed following antiendrocrine therapy, or those with hormone receptor-positive, human epidermal receptor 2-negative advanced breast cancer (BC) not previously treated with endocrine therapy (ET). This retrospective review showed that outcomes appeared better in patients without prior ET exposure and in patients with disease recurrence >12 months following adjuvant ET.

Read More